DG DISPATCH - AAN: Pergolide improves restless legs symptoms
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - AAN: Pergolide improves restless legs symptoms

By Richard Robinson
Special to DG News

SAN DIEGO, CA -- May 2, 2000 -- Pergolide decreases limb movements and improves sleep in restless legs syndrome (RLS), according to a study presented Monday (May 1) at the 52nd Annual Meeting of the American Academy of Neurology, in San Diego, CA.

Pergolide, a long-acting D1 and D2 dopamine receptor agonist, has been shown to be effective for RLS in short-term, double-blind trials.

To test its efficacy in the long-term, Karen Stiasny, MD, a neurologist at Philipps University of Marburg, in Germany, and colleagues followed patients from their double-blind trial for more than a year on open-label pergolide.

Twenty-two out of 28 eligible patients participatedin the trial. After a mean follow-up of 426 days, patients showed persistent improvement of better than 66 percent on the periodic limb movement index during both sleep and wakefulness compared to the pre-treatment baseline. They also showed significant improvements in total sleep time, sleep efficiency, and physician-rated clinical global impression.

Patients rated their RLS symptoms to be improved compared to baseline, falling from 4.8 to 1.7 on a 10-point severity scale (p=0.0001), and reported continued satisfaction with their sleep quality, rising from 2.4 to 5.7 on a seven-point satisfaction scale (p=0.0001). Dopaminergic side effects were controlled with domperidone in those patients who required it.

"There was a persistent, significant effect of low-dose pergolide on all primary symptoms of RLS," Dr. Stiasny concluded.

RLS is a neurologic movement disorder marked by dysesthesias and motor restlessness in both sleep and wakefulness.

The study, titled, "Long-term effect of pergolide in the treatment of restless legs syndrome," was supported by Lilly Deutschland.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities